Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico

Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infa...

Full description

Saved in:
Bibliographic Details
Main Authors: José Luis Huerta, Robyn Kendall, Luka Ivkovic, Carlos Molina, Amy W. Law, Diana Mendes
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Vaccines
Subjects:
cost-effectiveness
respiratory syncytial virus (RSV)
RSVpreF vaccine
maternal immunization
Mexico
economic evaluation
Online Access:https://www.mdpi.com/2076-393X/13/1/77
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items